Document:USA 21 CFR Part 809 06-May-2024: Difference between revisions
From GxPlex
gxplex>GxPlexBot Import from GxPlex Excel |
Remove static References table, superseded by live #ask in Template:DocumentData (GxPlexBot) Â |
||
| (4 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
{{DocumentData | |||
 | |||
|reference=USAÂ 21 CFR Part 809Â 06-May-2024 | |reference=USAÂ 21 CFR Part 809Â 06-May-2024 | ||
|validity_area=USA | |validity_area=USA | ||
| Line 29: | Line 14: | ||
|contributors= | |contributors= | ||
}} | }} | ||
Latest revision as of 14:15, 16 July 2026
| Document information | |
|---|---|
| Reference | USA 21 CFR Part 809 06-May-2024 |
| Validity area | USA |
| Scope(s) | G |
| Document name | 21 CFR Part 809 |
| Version / Revision | 06-May-2024 |
| Status | Current |
| Document type | Legal act |
| Language(s) | EN |
| Description | |
| Official source | — |
| Restricted access | No |
| Submitted by | Florian Adragna |
| Contributors | |
References
| Scope | Document part | Language | Preview | |
|---|---|---|---|---|
| USA 21 CFR Part 809 06-May-2024 § 809.3 (a) | G | § 809.3 (a) | EN | § 809.3 Definitions. (a) In vitro diagnostic products are those reagents, instruments, and systems intended for use in the diagnosis of disease or o… |
